These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9712460

  • 1. Serum concentrations and side effects in psychiatric patients during risperidone therapy.
    Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K.
    Ther Drug Monit; 1998 Aug; 20(4):380-4. PubMed ID: 9712460
    [Abstract] [Full Text] [Related]

  • 2. Risperidone plasma levels, clinical response and side-effects.
    Riedel M, Schwarz MJ, Strassnig M, Spellmann I, Müller-Arends A, Weber K, Zach J, Müller N, Möller HJ.
    Eur Arch Psychiatry Clin Neurosci; 2005 Aug; 255(4):261-8. PubMed ID: 15565299
    [Abstract] [Full Text] [Related]

  • 3. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
    Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML.
    Psychopharmacology (Berl); 1999 Dec; 147(3):300-5. PubMed ID: 10639689
    [Abstract] [Full Text] [Related]

  • 4. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone.
    Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM.
    Eur J Clin Pharmacol; 2010 Nov; 66(11):1109-17. PubMed ID: 20563569
    [Abstract] [Full Text] [Related]

  • 5. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
    Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E.
    Psychopharmacology (Berl); 2001 Jan 01; 153(2):238-43. PubMed ID: 11205425
    [Abstract] [Full Text] [Related]

  • 6. Impact of Ageing on Serum Concentrations of Risperidone and Its Active Metabolite in Patients with Known CYP2D6 Genotype.
    Molden E, Waade RB, Hoff M, Haslemo T.
    Basic Clin Pharmacol Toxicol; 2016 Nov 01; 119(5):470-475. PubMed ID: 27145399
    [Abstract] [Full Text] [Related]

  • 7. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
    Gunes A, Spina E, Dahl ML, Scordo MG.
    Ther Drug Monit; 2008 Oct 01; 30(5):628-33. PubMed ID: 18708991
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
    Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, de Vries R, Kaneko S.
    Ther Drug Monit; 2003 Jun 01; 25(3):287-93. PubMed ID: 12766554
    [Abstract] [Full Text] [Related]

  • 11. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
    Yasui-Furukori N, Mihara K, Kondo T, Kubota T, Iga T, Takarada Y, De Vries R, Kaneko S, Tateishi T.
    J Clin Pharmacol; 2003 Feb 01; 43(2):122-7. PubMed ID: 12616663
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM, Kim KA, Cho HK, Jung IG, Park PW, Byun WT, Park JY.
    Clin Pharmacol Ther; 2005 Nov 01; 78(5):520-8. PubMed ID: 16321618
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
    Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB.
    Clin Pharmacokinet; 2015 Dec 01; 54(12):1259-72. PubMed ID: 26129906
    [Abstract] [Full Text] [Related]

  • 16. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine.
    Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia A.
    Ther Drug Monit; 2001 Jun 01; 23(3):223-7. PubMed ID: 11360029
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes.
    Cho HY, Lee YB.
    Arch Pharm Res; 2006 Jun 01; 29(6):525-33. PubMed ID: 16833023
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Plasma risperidone concentrations during combined treatment with sertraline.
    Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A.
    Ther Drug Monit; 2004 Aug 01; 26(4):386-90. PubMed ID: 15257068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.